Logo Prima Biomed


Welcome to the Newsroom

07 July 2015

Positive scientific advice from the European Medicines Agency
Prima BioMed erhält positiven Scientific Advice der Europäischen Arzneimittelbehörde EMA für das Hauptprodukt IMP321

ENGLISH

The EMA has now confirmed in writing its endorsement of the development program of IMP321 in metastatic breast cancer.  

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”), a leading immuno-oncology company, is pleased to announce that it has received positive Scientific Advice from the European Medicines Agency (“EMA” or the “Agency”) on the development path for its lead product, IMP321 in metastatic breast cancer.

(...)






GERMAN

Sydney / Leipzig, 7. Juli 2015 – Prima BioMed Ltd. (ISIN US74154B2034), ein führendes Unternehmen im Bereich der Immunonkologie, hat von der Europäischen Arzneimittelbehörde EMA (European Medicines Agency) einen positiven Scientific Advice für die Entwicklung des Hauptprodukts IMP321 bei metastasierendem Brustkrebs erhalten.

(...)